Ellagic acid
From Glioblastoma Treatments
| Property | Information |
|---|---|
| Drug Name | Ellagic Acid |
| FDA Approval | No (Utilized as a dietary component; not FDA-approved for cancer treatment) |
| Used for | Investigational use in cancer prevention and treatment; noted for potential anti-cancer properties in laboratory studies |
| Clinical Trial Phase | Preclinical and early clinical trials (e.g., prostate cancer study at UCLA) |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Not specifically documented; as a naturally occurring compound in fruits and nuts, it is generally considered safe |
| OS without | Not specified |
| OS with | Not applicable; current research focuses on biochemical effects and prevention metrics like PSA doubling time in prostate cancer |
| PFS without | Not specified |
| PFS with | Not applicable; direct impacts on progression-free survival in cancer patients are not yet established |
| Usefulness Rating | 3 |
| Usefulness Explanation | Not specified |
| Toxicity Level | Not specified |
| Toxicity Explanation | Not specified |
Notes: Ellagic Acid, found in various fruits and nuts, exhibits anti-cancer properties in laboratory experiments, including the inhibition of cell division and induction of apoptosis. Although clinical trials specific to brain cancer are lacking, a study with prostate cancer patients demonstrated that pomegranate juice, rich in ellagitannins (ellagic acid precursors), significantly slowed the increase in PSA levels, suggesting a potential for cancer management. These findings indicate ellagic acid's promise in cancer prevention and warrant further clinical investigation to confirm its efficacy and therapeutic application in oncology.
From Ben Williams Book: Not specified
Loading comments...
